Get started
Author

Fulya Sen Nikitas

Observed names: FULYA SEN NIKITAS, Fulya Nikitas
ORCID: 0009-0002-6123-1622
Observed ORCID: 0009-0002-6123-1622
OpenAlex ID: A5049554387
Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis
2022 · Kiera Heffernan, Fulya Sen Nikitas, et al. · Gynecologic Oncology · 30
PDF
Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England
2023 · Scott Goulden, Kiera Heffernan, et al. · International Journal of Gynecological Cancer · 7
PDF
Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM
2025 · Francesca Palandri, Nicolaas Schaap, et al. · Blood · 2
PDF
The Relationship between Anemia, Transfusion Dependence, Quality of Life and Survival in Myelofibrosis
2024 · Aaron T. Gerds, Fulya Sen Nikitas, et al. · Blood · 2
PDF
Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison
2026 · Francesca Palandri, Venediktos Kapetanakis, et al. · Annals of Hematology · 1
PDF
Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis
2025 · Andrew Kuykendall, Francesca Palandri, et al. · Blood · 1
PDF
Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib
2025 · Vikas Gupta, Francesca Palandri, et al. · Blood · 1
Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1
2025 · Raajit Rampal, Prithviraj Bose, et al. · Blood · 1
PDF
Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison
2024 · Francesca Palandri, Venediktos Kapetanakis, et al. · Blood · 1
Comparison of survival outcomes between dostarlimab and comparator treatments (tx) in patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC) in England: Matching-adjusted indirect comparisons (MAICs).
2022 · Scott Goulden, Kiera Heffernan, et al. · Journal of Clinical Oncology · 1
Msr12 Evaluating Clinical Outcome Assessments in Low-risk Myelodysplastic Syndromes Through Development of a Comprehensive Conceptual Model Based on Targeted Literature Reviews and Clinician Interviews
2026 · Anna P. Cardellino, FULYA SEN NIKITAS, et al. · Value in Health
Clinical outcomes with ruxolitinib in Janus kinase inhibitor–naive patients with myelofibrosis and new or worsening anemia or thrombocytopenia: post hoc analysis of the phase 3 SIMPLIFY-1 trial
2026 · Vikas Gupta, Francesca Palandri, et al. · NCODA Oncology and Hematology Meeting Abstracts
EE67 Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection
2025 · Louis S. Matza, Alan Martin, et al. · Value in Health
RWD55 Deep Real-World Analysis of Patients With Myelofibrosis Using Natural Language Processing and Machine Learning: A Methods Description
2025 · FULYA SEN NIKITAS, TIM d'ESTRUBE, et al. · Value in Health
Works count: 14
Citation count: 47
H-index: 2
I10-index: 1
Year
Topic
Type